(1 - 10 from 14
)
Gilead Sciences shares rise after interim data from phase 2 hep C trial
www.proactiveinvestors.com
[Proactive Investors USA & Canada] - “These results indicate that adding GS to sofosbuvir-based regimens may enhance SVR rates, potentially offering HCV genotype 1 infected patients a convenient 12-week course of oral therapy,” said Professor Edward Gane, the principal investigator
Achillion Achieves 100% SVR12 in Phase 2 Trial Evaluating
www.globenewswire.com
- Achillion achieves 100% SVR12 in six-week regimen with combination of ACH and sofosbuvir for treatment-naïve genotype 1 HCV Achillion...
Gilead Announces 100 Percent Sustained Virologic Response Rate (SVR4)...
investors.gilead.com
... offering HCV genotype 1 infected patients a convenient 12-week course of oral therapy,” said Professor Edward Gane , MD, Deputy Director and Hepatologist, ...
GS plus ribavirin rapidly suppresses HCV but most patients...
www.aidsmap.com
Edward Gane from Auckland City Hospital in New Zealand presented the latest data from the ELECTRON trial. As reported at the Liver Meeting ...
sorted by relevance / date